Dr Lal PathLabs profit rises 27% in Q2
after close1 source ↓machine-written, see hownot a recommendation
- LALPATHLAB close
- ₹1,926
- On the day
- +2.04%
- 52-week high
- ₹3,309
- 52-week low
- ₹1,273
Dr Lal PathLabs reported a strong second-quarter performance for FY27, with consolidated net profit rising 27% year on year to ₹194 cr for the quarter ended September 2026, compared with ₹152 cr a year earlier. Total income increased 20% to ₹908 cr from ₹755 cr, while profit before tax rose 28% to ₹261 cr. Total expenses grew 17% to ₹648 cr, slower than the growth in income. 📈
The board also declared a second interim dividend of ₹5 per equity share, representing a 50% payout for FY27. The record date is 11 Nov 2026, and the dividend is scheduled to be paid within 30 days of declaration. The payout adds a shareholder-return catalyst to the earnings update while the higher profit growth indicates operating leverage in the diagnostics business. 💊
OI Charts data showed the stock closed at ₹1,926 on 03 Nov 2026, up 2.0% on the day on volume of 231,854 shares. The stock gained 1.3% over five sessions but remained down 3.1% over 20 sessions. Its 52-week range stood between ₹1,273, recorded on 23 Mar 2026, and ₹3,309, recorded on 19 Nov 2025.
The next market focus is the 11 Nov record date and the company’s detailed earnings disclosures on revenue mix, test volumes, pricing and margins. These factors will indicate whether the 20% income growth is broad-based across the diagnostics network and whether expense growth remains below revenue growth. The ₹1,926 close and the recent 20-session decline provide the immediate price context for assessing the market’s response to the results.
Source: Zee Business, 04 Nov 2026
Not investment advice. For informational purposes only.